68
Participants
Start Date
September 30, 2011
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
sipuleucel-T
Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
leuprolide acetate
45.0 mg depot injection, 2 doses 6 months apart
NYOH Albany Cancer Center at Patroon Creek, Albany
Community Care Physicians, PC, Albany
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Grand Strand Urology, Myrtle Beach
Urology Center of Alabama, Homewood
Urology San Antonio Research, San Antonio
The Urology Center of Colorado, Denver
Comprehensive Cancer Centers of Nevada, Las Vegas
Keck Hospital of USC, Los Angeles
LAC + USC Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
University of California San Diego / Moores Cancer Center, La Jolla
Virginia Mason Medical Center, Seattle
Seattle Cancer Care Alliance, Seattle
Lead Sponsor
Dendreon
INDUSTRY